Our Paris Technology and Life Sciences team advised Surge, an innovative deeptech company specializing in in-depth understanding of the immune system using AI, in its €7.5 million fundraising.
Created in 2021, Surge’s mission is to deliver accurate predictions for complication-free surgeries.
This round table was led by Eurazeo and included Kima Ventures, Teampact, Malakoff Humanis and Bpifrance.
This funding will enable Surge to finalize the industrialization of their first product PreCyte, its predictive test for postoperative complications. It will also enable the opening of SurgeLab, a premier laboratory specialized in decrypting the immune system.
The Goodwin team was led by Xavier Leroux and included Augustin Piqueras on corporate aspects.